Single-dose LSD drug successfully treats depression in key human trial

Definium Therapeutics has announced strong results in a phase 3 trial of its single-dosed lysergide (LSD) drug DT120 in treating adults with major depressive disorder (MDD), meeting its primary goal and all key secondary efficacy endpoints in the first trial of its kind.Continue ReadingCategory: Men…

View Post on Scour ↗

More from Refractor on Scour.